Want to see SE:PROGEN full AI Analyst Report?
PROGEN Stock Chart & Stats
kr0.75
-kr0.32(-6.69%)
At close: 4:00 PM EST
kr0.75
-kr0.32(-6.69%)
Day’s Range― - ―
52-Week Rangekr0.09 - kr0.87
Previous CloseN/A
Volume7.01K
Average Volume (3M)300.11K
Market Cap
kr83.10M
Enterprise Valuekr6.47
Total Cash (Recent Filing)kr9.07M
Total Debt (Recent Filing)kr5.30M
Price to Earnings (P/E)―
Beta-1.16
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.82
Shares Outstanding532,703,900
10 Day Avg. Volume460,844
30 Day Avg. Volume300,114
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.08
Revenue Forecast (FY)kr1.23M
Bulls Say, Bears Say
Bulls Say
Moderate LeverageDebt-to-equity of about 0.20 and debt of roughly 5.3M against equity of 26.5M indicate leverage is not yet excessive. This cushion can support operations and reduce near-term solvency pressure, although it does not eliminate the need to fund ongoing losses.
Positive Equity BasePositive equity of approximately 26.5M provides a capital base above reported debt and is a more resilient starting point than a balance sheet already in deficit. It may preserve financing flexibility, though falling equity remains a warning if losses persist.
Reduced Operating Cash BurnOperating cash flow loss narrowed from about -44.7M in 2024 to -23.8M in 2025. If sustained through cost control or improving commercialization, this would extend financial runway, although cash generation remains negative and the improvement is not yet sufficient.
Bears Say
Declining Revenue BaseRevenue declined about 17% in 2025 versus 2024, while sales remain small. A shrinking revenue base limits operating leverage and makes it harder for the diagnostics offering to absorb fixed costs, weakening the visibility of a durable path to scale.
Severely Negative ProfitabilityProfitability is deeply negative, with 2025 gross profit negative and gross margin around -63%, alongside large operating and net losses. This indicates current sales do not cover delivery and operating costs, creating a material barrier to self-funded growth.
Persistent Cash BurnOperating and free cash flow have been negative in every year provided, and 2025 free cash flow worsened about 38% versus 2024. Continued burn implies dependence on external funding, while declining equity raises dilution or balance-sheet risk.
PROGEN FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was kr0.09 and its highest was kr0.87 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is kr83.10M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Aug 31, 2026 which is in 5 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Feb 26, 2026. The company reported -kr0.151 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 532,703,900 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -kr0.151 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -8.8%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in SE:PROGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Technical Analysis
Immunovia AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―